1. What is the name of the quantum processor by Google that achieved the first “verifiable” quantum advantage?
[A] Willow
[B] Bristlecone
[C] Sycamore
[D] Falcon
Show Answer
Correct Answer: A [Willow]
Notes:
Google announced that its quantum processor Willow has achieved the first “verifiable” quantum advantage. Quantum advantage means a quantum computer can outperform a classical computer in practice. The announcement was accompanied by an open-access paper in Nature by the Google Quantum AI and Collaborators team. Willow ran a new algorithm, Quantum Echoes, 13,000 times faster than the best classical algorithm on a supercomputer. The experiment used a technique called out-of-time-order correlator (OTOC) to track how information scrambles in quantum systems. OTOC measures how quantum information spreads, is scrambled, and can be “unscrambled” using time-reversal. Willow’s processor precisely controlled quantum bits (qubits) in a chaotic quantum system for the experiment.
2. In October 2025, Mounjaro became India’s top-selling drug by value, overtaking which antibiotic?
[A] Amoxicillin
[B] Augmentin
[C] Doxycyclin
[D] Azithromycin
Show Answer
Correct Answer: B [Augmentin]
Notes:
Eli Lilly’s weight-loss drug Mounjaro became India’s top-selling drug by value in October 2025. It overtook GlaxoSmithKline’s (GSK) Augmentin, a widely used antibiotic. Mounjaro earned ₹1 billion ($11.38 million) in October, while Augmentin made ₹800 million. By volume, Augmentin sold 5,784 units, whereas Mounjaro sold only 85 units due to its high price. Mounjaro helps control blood sugar and slow digestion and belongs to the GLP-1 receptor agonist class used for obesity and diabetes. It was launched in India in March 2025 and has earned ₹3.33 billion till October. Mounjaro’s consumption was 10 times higher than rival Wegovy by Novo Nordisk, launched in June 2025. Eli Lilly sold 262,000 units, while Novo Nordisk sold 26,000 units in October.
3. The Visible Emission Line Coronagraph (VELC) is the primary payload of which Indian space mission?
[A] Chandrayaan-3
[B] Chandrayaan-2
[C] Mangalyaan-2
[D] Aditya-L1
Show Answer
Correct Answer: D [Aditya-L1]
Notes:
In November 2025, scientists from the Indian Institute of Astrophysics (IIA) collaborated with the National Aeronautics and Space Administration (NASA) to estimate key parameters of a Coronal Mass Ejection (CME). They used data from the Visible Emission Line Coronagraph (VELC) payload onboard India’s Aditya-L1 mission. VELC is the main payload of Aditya-L1, India’s first solar observatory placed 1.5 million kilometres from Earth. It is an internally occulted solar coronagraph capable of imaging, spectroscopy, and spectro-polarimetry near the solar limb.
4. What kind of disease is African Swine Fever (ASF) that was recently seen in news?
[A] Fungal disease
[B] Viral disease
[C] Bacterial disease
[D] None of the Above
Show Answer
Correct Answer: B [Viral disease]
Notes:
The Assam Government recently banned inter-district movement of live pigs to stop the spread of African Swine Fever (ASF), a rising concern in the region. African Swine Fever (ASF) is a highly contagious and deadly viral disease affecting pigs and wild boar, with mortality up to 90–100%. It is not zoonotic, meaning it does not infect humans or other livestock. First found in sub-Saharan Africa, ASF is now present across Europe, Asia and Africa, with India reporting its first cases in 2020 in Assam and Arunachal Pradesh.
5. What is the name of India’s first private commercial orbital rocket unveiled by Skyroot Aerospace?
[A] Agni-I
[B] Gaganyaan
[C] Aditya-I
[D] Vikram-I
Show Answer
Correct Answer: D [Vikram-I]
Notes:
Skyroot Aerospace inaugurated its Infinity Campus in Hyderabad and virtually unveiled Vikram-I, India’s first private commercial orbital rocket. Vikram-I is capable of placing satellites into Earth orbit. This launch marks a major milestone for India’s growing private space sector. The private space sector in India was opened to entrepreneurs three years ago. The development highlights rising startup participation in advanced space technology. It reflects India’s shift toward innovation-driven and private-led space missions.
6. Where was India’s first single-use bioprocess design and scale-up facility inaugurated in November 2025?
[A] Bengaluru
[B] Kolkata
[C] Hyderabad
[D] Chennai
Show Answer
Correct Answer: C [Hyderabad]
Notes:
Telangana’s 1 Bio, India’s first single-use bioprocess design and scale-up facility, was inaugurated at Genome Valley, Hyderabad. It was created to solve the lack of affordable bioprocess scale-up infrastructure despite Telangana’s strong biotech talent. The facility supports start-ups and big companies with end-to-end process development and pilot validation. It was developed by the Government of Telangana, Telangana Lifesciences, Department of Biotechnology (DBT), Government of India, and Telangana Industrial Infrastructure Corporation (TGIIC). It has 500-litre bioreactors, advanced processing systems, and analytical labs.
7. What is the name of India’s first manned deep-sea submersible mission?
[A] Gaganyaan
[B] Samudrayaan
[C] Sagaryaan
[D] Chandrayaan
Show Answer
Correct Answer: B [Samudrayaan]
Notes:
Samudrayaan is India’s first manned deep-ocean submersible mission to reach 6,000 metres depth. Testing is delayed due to late supply of syntactic foam from France, now expected by year-end after testing in Norway. The project is led by National Institute of Ocean Technology under the Ministry of Earth Sciences. A steel model has been tested up to 100 metres; a 500-metre trial is planned by April next year. The final titanium hull, built by Indian Space Research Organisation, will be tested in Russia. The mission will carry three crew members to collect seabed soil and rocks for future deep-sea mining.
8. Leprosy (Hansen’s disease), that was recently seen in news, is caused by which agent?
[A] Bacteria
[B] Virus
[C] Fungus
[D] Protozoa
Show Answer
Correct Answer: A [Bacteria]
Notes:
The National Human Rights Commission (NHRC) reported that 97 central and state laws still have provisions discriminating against persons affected by leprosy. Leprosy (Hansen’s disease) is a chronic bacterial infection caused by bacteria Mycobacterium leprae affecting skin, peripheral nerves, and eyes, which can cause permanent disabilities if untreated. The bacteria spread through droplets from the nose and mouth during close, frequent contact with untreated cases. India’s prevalence rate decreased from 57.2 per 10,000 in 1981 to 0.57 per 10,000 in 2025, achieving national elimination status in 2005.
9. Which institution has developed an ingestible device capable of directly sampling bacteria from the small intestine?
[A] IIT Bombay
[B] IIT Delhi
[C] IIT Madras
[D] IIT Kanpur
Show Answer
Correct Answer: B [IIT Delhi]
Notes:
Researchers at the Indian Institute of Technology Delhi have developed an ingestible device that can directly sample bacteria from the small intestine. The innovation helps overcome limitations of current methods like endoscopy or stool analysis, which do not accurately reflect upper gut conditions. The pill-sized device remains closed in the stomach and opens only in the intestine to collect bacterial samples, then reseals safely. It uses an enteric-coated gelatin cap that dissolves at intestinal pH, allowing fluid and microbes to enter sampling chambers. The study was conducted in collaboration with the All India Institute of Medical Sciences Delhi and funded by the Indian Council of Medical Research.
10. Which institute has developed a nanoparticle-based therapy for Alzheimer’s Disease (AD)?
[A] Institute of Nano Science and Technology (INST), Mohali
[B] Indian Institute of Technology, Delhi
[C] All India Institute of Medical Sciences, New Delhi
[D] Council of Scientific and Industrial Research – National Chemical Laboratory, Pune
Show Answer
Correct Answer: A [Institute of Nano Science and Technology (INST), Mohali]
Notes:
Researchers at the Institute of Nano Science and Technology (INST), Mohali, developed a new nanoparticle-based therapy for Alzheimer’s Disease (AD). Conventional AD therapies target only one feature like amyloid aggregation or oxidative stress, giving limited benefit. The new therapy uses nanoparticles integrating polyphenol (from green tea), dopamine (a neurotransmitter), and tryptophan (an amino acid). These form EGCG-dopamine-tryptophan nanoparticles (EDTNPs) targeting amyloid aggregation, oxidative stress, inflammation, and neuronal degeneration simultaneously.